Nav: Home

Dana-Farber scientists find new drug targets in aggressive cancers

November 05, 2018

BOSTON - Scientists have discovered a previously unknown molecular vulnerability in two rare, aggressive, and hard-to-treat types of cancer, and say it may be possible to attack this weakness with targeted drugs.

Reporting in Nature Cell Biology, researchers at Dana-Farber Cancer Institute show that these two cancers - synovial sarcoma and malignant rhabdoid tumors - are dependent on a newly characterized "molecular machine" called ncBAF, which plays unique roles in regulating gene activity. The scientists showed that biologically and chemically disabling components of ncBAF -- which is made up of several unique protein subunits - specifically impaired the proliferation of two types of cancer cell lines which share a common disruption.

"This is one of the first suggestions toward a route for therapeutic intervention in these intractable, aggressive cancers," said Cigall Kadoch, PhD, of Dana-Farber Cancer Institute, senior author of the report in Nature Cell Biology. "These findings identify new, cancer-specific targets which may be extendable to other cancer types as well."

Synovial sarcoma is a rare cancer of soft tissues that typically is diagnosed in young adults. Malignant rhabdoid tumors are also rare but are very aggressive and usually develop in children under the age of two. They can affect the brain, kidney, and other organs.

Recent work by Kadoch's team as well as other groups has implicated these molecular machines, called chromatin-remodeling complexes, in the development and maintenance of cancer. These complexes are clusters of proteins that remodel the way the DNA in a cell is packaged - and in doing so, help regulate which genes are turned on and off. Each of the complexes is made up of numerous protein subunits.

Kadoch's research has focused on a category of chromatin remodeling complexes known as the SWI/SNF family. There are three types of complexes in the family - cBAF, PBAF, and ncBAF. Two weeks ago, in Cell, the Kadoch group reported the order of assembly and modular organization of these complexes for the first time. Importantly, these chromatin remodelers travel to various locations on the DNA genome within the cell and regulate which genes are turned on, and when, to generate the cell's proteins needed at various times. It's estimated that 20 percent of human cancers are associated with mutations in the genes that code for the chromatin-remodeling complex subunits, resulting in disruption of gene expression and leading to the development of tumors.

In the current study, the researchers report that the ncBAF complex (nc stands for non-canonical) differs from the other two complexes (cBAF and PBAF) in several ways, including where on the genome it acts. In addition, ncBAF is different because it contains two subunits, BRD9 and GLTSCR1, that aren't parts of any other complexes, and lacks subunits that are found in other complexes.

Most intriguingly - and relevant for cancer - the researchers found that ncBAF function is specifically required by synovial sarcoma and malignant rhabdoid tumors to maintain their cell division and growth. Owing to its dependence in these cancers, ncBAF is termed a "synthetic lethal target," suggesting that disrupting ncBAF could be a viable approach to treating these tumors.

Kadoch and her colleagues are particularly interested in the BRD9 subunit of the ncBAF complex, because there are existing small molecule probes that can block BRD9 activity, as well as experimental agents, known as protein degraders, that are designed to eliminate BRD9 from cells.

"This was an unexpected target, and these findings are already being explored pre-clinically" in hopes of treating the two rare cancers, Kadoch says. Co-first authors of the work are Brittany Michel, Andrew D'Avino, and Seth Cassel.
The research was supported in part by NIH DP2 New Innovator Award #1DP2CA195762-01, American Cancer Society Research Scholar Award RSG-14-051-01-DMC, and Pew-Stewart Scholars in Cancer Research Grant award to CK, and NIH grant 5T32GM095450-04. Kadoch is a scientific founder, fiduciary Board of Directors member, Scientific Advisory Board member, shareholder, and consultant for Foghorn Therapeutics, Inc.

About Dana-Farber

Dana-Farber Cancer Institute is one of the world's leading centers of cancer research and treatment. It is the only center ranked in the top 4 of U.S. News and World Report's Best Hospitals for both adult and pediatric cancer care.

Dana-Farber's mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. We provide the latest in cancer for adults through Dana-Farber/Brigham and Women's Cancer Care and for children through Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world.

Dana-Farber Cancer Institute

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at